Pretomanid: First Approval-Reference-Cited by-同舟云学术

Pretomanid: First Approval

Published:2019-10-03 Issue:16 Volume:79 Page:1797-1803
ISSN:0012-6667
Container-title:Drugs
language:en
Short-container-title:Drugs

Author:

Keam Susan J.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical)

Link

http://link.springer.com/content/pdf/10.1007/s40265-019-01207-9.pdf

Reference31 articles.

1. Stover CK, Warrener P, VanDevanter DR, et al. A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis. Nature. 2000;405(6789):962–6.

2. TB Alliance. The pandemic: a global threat. 2019. https://www.tballiance.org/why-new-tb-drugs/global-pandemic . Accessed 28 Aug 2019.

3. Gothi D, Joshi JM. Resistant TB: newer drugs and community approach. Recent Pat Anti Infect Drug Disc. 2011;6(1):27–37.

4. Murray S, Mendel C, Spigelman M. TB Alliance regimen development for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20(12):38–41.

5. TB Alliance. Novartis sets deal to seek new drugs for fighting TB. 2004. https://www.tballiance.org/news/novartis-sets-deal-seek-new-drugs-fighting-tb . Accessed 27 Aug 2019.

Cited by 158 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a proliposomal pretomanid dry powder inhaler as a novel alternative approach for combating pulmonary tuberculosis;International Journal of Pharmaceutics;2024-10

2. An Update to Novel Therapeutic Options for Combating Tuberculosis: Challenges and Future Prospectives;Current Pharmaceutical Biotechnology;2024-10

3. Development of narrow-spectrum topoisomerase-targeting antibacterials against mycobacteria;European Journal of Medicinal Chemistry;2024-10

4. Tricyclic Benzo[1,3]oxazinyloxazolidinones as Potent Antibacterial Agents against Drug-Resistant Pathogens;Journal of Medicinal Chemistry;2024-09-05

5. Key challenges in TB drug discovery: A perspective;Bioorganic & Medicinal Chemistry Letters;2024-09